3 / 19
Page 35
I n t e r n a t i o n a l C o n f e r e n c e o n
Neurological Disorders,
Stroke and CNS
October 22-23 , 2018
Athens , Greece
Journal of Neurology and Neuroscience
ISSN: 2171-6625
Stroke and CNS 2018
O
ur research is focused on the identification and characterization of factors relevant to obesity and/or the metabolic syndrome
that modulates brain aging or can manipulate the conversion of normal brain aging to that hampered with Alzheimer’s
disease (AD). To achieve that, we have used biochemical, molecular, cell biology and
in vivo
models to screen, identify and
characterize our lead product under development, Memtin (a leptin product). Leptin is an adipocyte hormone, thought to control
energy homeostasis and known to have pleiotropic activities. Data suggest that leptin can modulate memory and cognition
through receptors in the hippocampus, where it is expressed at high density, following transport from the periphery via a natural
saturable transporter in the blood-brain-barrier. We further have accumulated data in support of leptin’s disease modifying
potential utilizing cell-based and animal models. Further, epidemiological studies in humans involving thousands of subjects
demonstrated an association of low leptin and a high risk for Alzheimer’s disease and a positive correlation between leptin levels
and hippocampal volume. Interventional studies are also in agreement. Thus, our approach involving repurposing an approved
drug as a replacement therapy for MCI/prodromal AD characterized by hypoleptinemia represents a novel solution for a huge
unmet medical need.
ntezapsidis@neurotez.comMemtin, a novel preventative and therapeutic for
Alzheimer’s disease
Nikolaos Tezapsidis and Jane M Johnston
Neurotez Inc, USA
J Neurol Neurosci 2018, Volume: 9
DOI: 10.21767/2171-6625-C3-015